Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Immunogenicity of a rheumatoid arthritis protective sequence when acquired through microchimerism.

Kanaan SB, Sensoy O, Yan Z, Gadi VK, Richardson ML, Nelson JL.

Proc Natl Acad Sci U S A. 2019 Sep 9. pii: 201904779. doi: 10.1073/pnas.1904779116. [Epub ahead of print]

PMID:
31501349
2.

Discovery of novel bacterial queuine salvage enzymes and pathways in human pathogens.

Yuan Y, Zallot R, Grove TL, Payan DJ, Martin-Verstraete I, Šepić S, Balamkundu S, Neelakandan R, Gadi VK, Liu CF, Swairjo MA, Dedon PC, Almo SC, Gerlt JA, de Crécy-Lagard V.

Proc Natl Acad Sci U S A. 2019 Sep 17;116(38):19126-19135. doi: 10.1073/pnas.1909604116. Epub 2019 Sep 3.

PMID:
31481610
3.

Obstetric Outcomes in Young Women with Breast Cancer: Prior, Postpartum, and Subsequent Pregnancies.

Ma KK, Preusse CJ, Stevenson PA, Winget VL, McDougall JA, Li CI, Gadi VK, Gammill HS.

Am J Perinatol. 2019 Feb 6. doi: 10.1055/s-0039-1678603. [Epub ahead of print]

PMID:
30726999
4.

Correction to: a Phase 2 Study of 16α-[18F]-Fluoro-17β-Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC).

Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA, Linden HM.

Mol Imaging Biol. 2019 Feb;21(1):191. doi: 10.1007/s11307-018-1287-7.

PMID:
30324461
5.

Prospective Study of Serial 18F-FDG PET and 18F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer.

Peterson LM, O'Sullivan J, Wu QV, Novakova-Jiresova A, Jenkins I, Lee JH, Shields A, Montgomery S, Linden HM, Gralow J, Gadi VK, Muzi M, Kinahan P, Mankoff D, Specht JM.

J Nucl Med. 2018 Dec;59(12):1823-1830. doi: 10.2967/jnumed.118.211102. Epub 2018 May 10.

6.

Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer.

Xu C, Nikolova O, Basom RS, Mitchell RM, Shaw R, Moser RD, Park H, Gurley KE, Kao MC, Green CL, Schaub FX, Diaz RL, Swan HA, Jang IS, Guinney J, Gadi VK, Margolin AA, Grandori C, Kemp CJ, Méndez E.

Clin Cancer Res. 2018 Jun 15;24(12):2828-2843. doi: 10.1158/1078-0432.CCR-17-1339. Epub 2018 Mar 29.

7.

Comprehensive statistical inference of the clonal structure of cancer from multiple biopsies.

Liu J, Halloran JT, Bilmes JA, Daza RM, Lee C, Mahen EM, Prunkard D, Song C, Blau S, Dorschner MO, Gadi VK, Shendure J, Blau CA, Noble WS.

Sci Rep. 2017 Dec 5;7(1):16943. doi: 10.1038/s41598-017-16813-4.

8.

Diffusion-weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER+/HER2- breast cancers.

Amornsiripanitch N, Nguyen VT, Rahbar H, Hippe DS, Gadi VK, Rendi MH, Partridge SC.

J Magn Reson Imaging. 2018 Jul;48(1):226-236. doi: 10.1002/jmri.25909. Epub 2017 Nov 27.

9.

Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer.

Chang AE, Wu QV, Jenkins IC, Specht JM, Gadi VK, Gralow JR, Salazar LG, Kurland BF, Linden HM.

Clin Breast Cancer. 2018 Feb;18(1):e143-e149. doi: 10.1016/j.clbc.2017.10.005. Epub 2017 Oct 9.

PMID:
29174203
10.

Practical Approach to Triple-Negative Breast Cancer.

Gadi VK, Davidson NE.

J Oncol Pract. 2017 May;13(5):293-300. doi: 10.1200/JOP.2017.022632. Review.

PMID:
28489980
11.

Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.

Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R, McNary TJ, Churakova Y, Cheung C, Triscott J, Pisapia D, Rao R, Mosquera JM, Robinson B, Faltas BM, Emerling BE, Gadi VK, Bernard B, Elemento O, Beltran H, Demichelis F, Kemp CJ, Grandori C, Cantley LC, Rubin MA.

Cancer Discov. 2017 May;7(5):462-477. doi: 10.1158/2159-8290.CD-16-1154. Epub 2017 Mar 22.

12.

Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.

Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQ.

Neuro Oncol. 2017 Jan;19(1):i1-i24. doi: 10.1093/neuonc/now197. Review.

13.

Breast Cancer Outlook for 2017: Keeping the Accelerator to the Floor.

Gadi VK, Gralow JR.

Oncology (Williston Park). 2016 Dec 1;30(12 Suppl 2):1-2, 15. No abstract available.

14.

Statistical Methods for Unusual Count Data: Examples From Studies of Microchimerism.

Guthrie KA, Gammill HS, Kamper-Jørgensen M, Tjønneland A, Gadi VK, Nelson JL, Leisenring W.

Am J Epidemiol. 2016 Nov 15;184(10):779-786. doi: 10.1093/aje/kww093.

15.

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.

Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Strychor S, Kiesel BF, Linden HM, Thompson JA, Swisher E, Chai X, Shepherd S, Giranda V, Specht JM.

Clin Cancer Res. 2016 Jun 15;22(12):2855-64. doi: 10.1158/1078-0432.CCR-15-2137. Epub 2016 Jan 22.

16.

The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model.

Birnbaum J, Gadi VK, Markowitz E, Etzioni R.

Ann Intern Med. 2016 Feb 16;164(4):236-43. doi: 10.7326/M15-0754. Epub 2016 Jan 12.

17.

Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base.

Flanagan MR, Rendi MH, Gadi VK, Calhoun KE, Gow KW, Javid SH.

Ann Surg Oncol. 2015 Oct;22(10):3264-72. doi: 10.1245/s10434-015-4668-z. Epub 2015 Jul 23.

18.

Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New.

Cho E, Schwemm AK, Rubinstein LM, Stevenson PA, Gooley TA, Ellis GK, Specht JM, Livingston RB, Linden HM, Gadi VK.

Clin Breast Cancer. 2015 Oct;15(5):e277-85. doi: 10.1016/j.clbc.2015.04.002. Epub 2015 Apr 24.

19.

The use of stereotactic radiosurgery for brain metastases from breast cancer: who benefits most?

Cho E, Rubinstein L, Stevenson P, Gooley T, Philips M, Halasz LM, Gensheimer MF, Linden HM, Rockhill JK, Gadi VK.

Breast Cancer Res Treat. 2015 Feb;149(3):743-9. doi: 10.1007/s10549-014-3242-x. Epub 2015 Feb 1.

20.

Male microchimerism and survival among women.

Kamper-Jørgensen M, Hjalgrim H, Andersen AM, Gadi VK, Tjønneland A.

Int J Epidemiol. 2014 Feb;43(1):168-73. doi: 10.1093/ije/dyt230. Epub 2013 Dec 17.

PMID:
24345850
21.

Preoperative MRI improves prediction of extensive occult axillary lymph node metastases in breast cancer patients with a positive sentinel lymph node biopsy.

Loiselle C, Eby PR, Kim JN, Calhoun KE, Allison KH, Gadi VK, Peacock S, Storer BE, Mankoff DA, Partridge SC, Lehman CD.

Acad Radiol. 2014 Jan;21(1):92-8. doi: 10.1016/j.acra.2013.10.001.

22.

A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).

Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA, Linden HM.

Mol Imaging Biol. 2014 Jun;16(3):431-40. doi: 10.1007/s11307-013-0699-7. Epub 2013 Oct 30. Erratum in: Mol Imaging Biol. 2019 Feb;21(1):191.

23.

In situ breast cancer and microchimerism.

Eun JK, Guthrie KA, Zirpoli G, Gadi VK.

Sci Rep. 2013;3:2192. doi: 10.1038/srep02192.

24.

Fetal cellular microchimerism in miscarriage and pregnancy termination.

Peterson SE, Nelson JL, Gadi VK, Gammill HS.

Chimerism. 2013 Oct-Dec;4(4):136-8. doi: 10.4161/chim.24915. Epub 2013 May 3.

25.

Predictors of male microchimerism.

Kamper-Jørgensen M, Mortensen LH, Andersen AM, Hjalgrim H, Gadi VK, Tjønneland A.

Chimerism. 2012 Jul-Dec;3(3):1-8. doi: 10.4161/chim.21968. Epub 2012 Jul 1.

26.

Prospective assessment of fetal-maternal cell transfer in miscarriage and pregnancy termination.

Peterson SE, Nelson JL, Guthrie KA, Gadi VK, Aydelotte TM, Oyer DJ, Prager SW, Gammill HS.

Hum Reprod. 2012 Sep;27(9):2607-12. doi: 10.1093/humrep/des244. Epub 2012 Jun 29.

27.

Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients.

Kurland BF, Gadi VK, Specht JM, Allison KH, Livingston RB, Rodler ET, Peterson LM, Schubert EK, Chai X, Mankoff DA, Linden HM.

EJNMMI Res. 2012 Jun 25;2(1):34. doi: 10.1186/2191-219X-2-34.

28.

Opposite effects of microchimerism on breast and colon cancer.

Kamper-Jørgensen M, Biggar RJ, Tjønneland A, Hjalgrim H, Kroman N, Rostgaard K, Stamper CL, Olsen A, Andersen AM, Gadi VK.

Eur J Cancer. 2012 Sep;48(14):2227-35. doi: 10.1016/j.ejca.2012.02.006. Epub 2012 Mar 5.

PMID:
22397765
29.

Soluble donor DNA and islet injury after transplantation.

Gadi VK, Nelson JL, Guthrie KA, Anderson CC, Boespflug ND, Redinger JW, Paul B, Dinyari P, Shapiro AM.

Transplantation. 2011 Sep 15;92(5):607-11. doi: 10.1097/TP.0b013e318228d799.

PMID:
21747325
30.

PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.

Dunnwald LK, Doot RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, Linden HM, Gadi VK, Kurland BF, Schubert EK, Muzi M, Mankoff DA.

Clin Cancer Res. 2011 Apr 15;17(8):2400-9. doi: 10.1158/1078-0432.CCR-10-2649. Epub 2011 Mar 1.

31.

Acquisition of the rheumatoid arthritis HLA shared epitope through microchimerism.

Yan Z, Aydelotte T, Gadi VK, Guthrie KA, Nelson JL.

Arthritis Rheum. 2011 Mar;63(3):640-4. doi: 10.1002/art.30160.

32.

Maternal and fetal microchimerism in granulocytes.

Sunku CC, Gadi VK, de Laval de Lacoste B, Guthrie KA, Nelson JL.

Chimerism. 2010 Jul-Sep;1(1):11-4. doi: 10.4161/chim.1.1.13098.

33.

Fetal microchimerism in breast from women with and without breast cancer.

Gadi VK.

Breast Cancer Res Treat. 2010 May;121(1):241-4. doi: 10.1007/s10549-009-0548-1. Epub 2009 Sep 19.

PMID:
19768535
34.

Fetal microchimerism and cancer.

Gadi VK.

Cancer Lett. 2009 Apr 8;276(1):8-13. doi: 10.1016/j.canlet.2008.07.025. Epub 2008 Oct 9. Review.

PMID:
18845390
35.

Case-control study of fetal microchimerism and breast cancer.

Gadi VK, Malone KE, Guthrie KA, Porter PL, Nelson JL.

PLoS One. 2008 Mar 5;3(3):e1706. doi: 10.1371/journal.pone.0001706.

36.

Skewed X-chromosome inactivation in scleroderma.

Uz E, Loubiere LS, Gadi VK, Ozbalkan Z, Stewart J, Nelson JL, Ozcelik T.

Clin Rev Allergy Immunol. 2008 Jun;34(3):352-5.

37.

Chronic lymphocytic lymphoma: another example of parental favoritism?

Gadi VK.

Leuk Lymphoma. 2007 Dec;48(12):2306-7. No abstract available.

PMID:
18067003
38.

Fetal microchimerism in women with breast cancer.

Gadi VK, Nelson JL.

Cancer Res. 2007 Oct 1;67(19):9035-8.

39.

Autoimmunity in CLL: grave consequences of gravidity?

Adams KM, Gadi VK.

Leuk Lymphoma. 2006 Aug;47(8):1445-6. No abstract available.

PMID:
16966248
40.

Soluble donor DNA concentrations in recipient serum correlate with pancreas-kidney rejection.

Gadi VK, Nelson JL, Boespflug ND, Guthrie KA, Kuhr CS.

Clin Chem. 2006 Mar;52(3):379-82. Epub 2006 Jan 5.

41.

Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy.

Bharara S, Sorscher EJ, Gillespie GY, Lindsey JR, Hong JS, Curlee KV, Allan PW, Gadi VK, Alexander SA, Secrist JA 3rd, Parker WB, Waud WR.

Hum Gene Ther. 2005 Mar;16(3):339-47.

PMID:
15812229
42.

A long-acting suicide gene toxin, 6-methylpurine, inhibits slow growing tumors after a single administration.

Gadi VK, Alexander SD, Waud WR, Allan PW, Parker WB, Sorscher EJ.

J Pharmacol Exp Ther. 2003 Mar;304(3):1280-4.

PMID:
12604707
43.

In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells.

Gadi VK, Alexander SD, Kudlow JE, Allan P, Parker WB, Sorscher EJ.

Gene Ther. 2000 Oct;7(20):1738-43.

44.

Gene therapy of cancer: activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase.

Secrist JA 3rd, Parker WB, Allan PW, Bennett LL Jr, Waud WR, Truss JW, Fowler AT, Montgomery JA, Ealick SE, Wells AH, Gillespie GY, Gadi VK, Sorscher EJ.

Nucleosides Nucleotides. 1999 Apr-May;18(4-5):745-57.

PMID:
10432677
45.

Components of human papillomavirus that activate transcription and support plasmid replication in human airway cells.

Gadi VK, Zou N, Liu JS, Cheng S, Broker TR, Sorscher EJ, Chow LT.

Am J Respir Cell Mol Biol. 1999 May;20(5):1001-6.

PMID:
10226070
46.

Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene.

Hughes BW, Wells AH, Bebok Z, Gadi VK, Garver RI Jr, Parker WB, Sorscher EJ.

Cancer Res. 1995 Aug 1;55(15):3339-45.

Supplemental Content

Support Center